EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 21 / Numéro 6-7 (Juin–Juillet 2005) Med Sci (Paris), 21 6-7 (2005) 627-633 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 21, Numéro 6-7, Juin–Juillet 2005
Page(s) 627 - 633
Section M/S revues
DOI https://doi.org/10.1051/medsci/2005216-7627
Publié en ligne 15 juin 2005
  1. Grateau G, Benson MD, Delpech M. Les amyloses. Paris : Flammarion Médecine-Sciences, 2000 : 580 p. [Google Scholar]
  2. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 1997; 337 : 898–909. [Google Scholar]
  3. Grateau G. Amyloses. In : Kahn MF, Peltier O, Meyer O, Piette JC, eds. Les maladies systémiques. Paris : Flammarion Médecine-Sciences, 2000 : 1279–308. [Google Scholar]
  4. Carter DB, Chou KC. A model for structure-dependent binding of Congo red to Alzheimer beta-amyloid fibrils. Neurobiol Aging 1998; 19: 37–40. [Google Scholar]
  5. Kaplan B, Shtrasburg S, Pras M. Micropurification techniques in the analysis of amyloid proteins. J Clin Pathol 2003; 56 : 86–90. [Google Scholar]
  6. Baltz ML, Caspi D, Evans DJ, et al. Circulating serum amyloid P component is the precursor of amyloid P component in tissue amyloid deposits. Clin Exp Immunol 1986; 66 : 691–700. [Google Scholar]
  7. Hawkins PN. Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Curr Opin Nephrol Hypertens 2002; 11 : 649–55. [Google Scholar]
  8. Sipe JD, Ed. Amyloid proteins: the beta sheet conformation and disease. Weinheim: Wiley-VCH, 2005 (sous presse). [Google Scholar]
  9. Canet D, Sunde M, Last AM, et al. Mechanistic studies of the folding of human lysozyme and the origin of amyloidogenic behavior in its disease-related variants. Biochemistry 1999; 38 : 6419–27. [Google Scholar]
  10. Hamilton JA, Benson MD. Transthyretin: A review from a structural perspective. Cell Mol Life Sci 2001; 58 : 1–31. [Google Scholar]
  11. Hofrichter J, Ross PD, Eaton WA. Kinetics and mechanism of deoxyhemoglobin S gelation: a new approach to understanding sickle cell disease. Proc Natl Acad Sci USA 1974; 71 : 4864–8. [Google Scholar]
  12. O’Nuallain B, Williams AD, Westermark P, Wetzel R. Seeding specificity in amyloid growth induced by heterologous fibrils. J Biol Chem 2004; 279 : 17490–9. [Google Scholar]
  13. Hurshman AR, White JT, Powers ET, Kelly JW. Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. Biochemistry 2004; 43 : 7365–81. [Google Scholar]
  14. Tompa P. Intrinsically unstructured proteins. Trends Biochem Sci 2002; 27 : 527–33. [Google Scholar]
  15. Niraula TN, Konno T, Li H, et al. Pressure-dissociable reversible assembly of intrinsically denatured lysozyme is a precursor for amyloid fibrils. Proc Natl Acad Sci USA 2004; 101 : 4089–93. [Google Scholar]
  16. Korenaga T, Fu X, Xing Y, et al. Tissue distribution, biochemical properties, and transmission of mouse Type A AApoAII amyloid fibrils. Am J Pathol 2004; 164 : 1597–606. [Google Scholar]
  17. Lundmark K, Westermark GT, Nystrom S, et al. Transmissibility of systemic amyloidosis by a prion-like mechanism. Proc Natl Acad Sci USA 2002; 99 : 6979–84. [Google Scholar]
  18. Mudher A, Lovestone S. Alzheimer’s disease : do tauists and baptists finally shake hands ? Trends Neurosci 2002; 25 : 22–6. [Google Scholar]
  19. Lee HG, Casadesus G, Zhu X, et al. Challenging the amyloid cascade hypothesis: senile plaques and amyloid-beta as protective adaptations to Alzheimer disease. Ann NY Acad Sci 2004; 1019 : 1–4. [Google Scholar]
  20. Kayed R, Head E, Thompson JL, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300 : 486–9. [Google Scholar]
  21. Kayed R, Sokolov Y, Edmonds B, et al. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem 2004; 279 : 46363–6. [Google Scholar]
  22. Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004; 94 : 1008–10. [Google Scholar]
  23. Skinner M, Sanchorawala V, Seldin DC, et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004; 140 : 85–93. [Google Scholar]
  24. Stangou AJ, Hawkins PN. Liver transplantation in transthyretin-related familial amyloid polyneuropathy. Curr Opin Neurol 2004; 17 : 615–20. [Google Scholar]
  25. Adamski-Werner SL, Palaninathan SK, Sacchettini JC, Kelly JW. Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. J Med Chem 2004; 47 : 355–74. [Google Scholar]
  26. Gertz MA, Lacy MQ, Dispenzieri A, et al. A multicenter phase II trial of 4’-iodo-4’deoxydoxorubicin (IDOX) in primary amyloidosis (AL). Amyloid 2002; 9 : 24–30. [Google Scholar]
  27. Cardoso I, Merlini G, Saraiva MJ. 4’-iodo-4’-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. FASEB J 2003; 17 : 803–9. [Google Scholar]
  28. Soto C, Kascsak RJ, Saborio GP, et al. Reversion of prion protein conformational changes by synthetic beta-sheet breaker peptides. Lancet 2000; 355 : 192–7. [Google Scholar]
  29. Gestwicki JE, Crabtree GR, Graef IA. Harnessing chaperones to generate small-molecule inhibitors of amyloid beta aggregation. Science 2004; 306 : 865–9. [Google Scholar]
  30. Kisilevsky R, Lemieux LJ, Fraser PE, et al. Arresting amyloidosis in vivo using small-molecule anionic sulphonates or sulphates: implications for Alzheimer’s disease. Nat Med 1995; 1 : 143–8. [Google Scholar]
  31. Kisilevsky R, Szarek WA, Ancsin JB, et al. Inhibition of amyloid A amyloidogenesis in vivo and in tissue culture by 4-deoxy analogues of peracetylated 2-acetamido-2-deoxy-alpha- and beta-d-glucose: implications for the treatment of various amyloidoses. Am J Pathol 2004; 164 : 2127–37. [Google Scholar]
  32. Pepys MB, Herbert J, Hutchinson WL. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002; 417 : 254–9. [Google Scholar]
  33. Dumoulin M, Dobson CM. Probing the origins, diagnosis and treatment of amyloid diseases using antibodies. Biochimie 2004; 86 : 589–600. [Google Scholar]
  34. O’Nuallain B, Wetzel R. Conformational Abs recognizing a generic amyloid fibril epitope. Proc Natl Acad Sci USA 2002; 99 : 1485–90. [Google Scholar]
  35. Hrncic R, Wall J, Wolfenbarger DA, et al. Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol 2000; 157 : 1239–46. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.